|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
19
|
|
pubmed:dateCreated |
2007-10-2
|
|
pubmed:abstractText |
Flavopiridol is a cyclin-dependent kinase inhibitor that enhances docetaxel-induced apoptosis in a sequence-specific manner. In vivo, docetaxel must precede flavopiridol by at least 4 h to induce this effect. We conducted a phase I trial of weekly, sequential docetaxel followed 4 h later by flavopiridol in patients with advanced solid tumors.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5841-6
|
|
pubmed:meshHeading |
pubmed-meshheading:17908977-Adult,
pubmed-meshheading:17908977-Aged,
pubmed-meshheading:17908977-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17908977-Deoxycytidine,
pubmed-meshheading:17908977-Drug Administration Schedule,
pubmed-meshheading:17908977-Drug Resistance, Neoplasm,
pubmed-meshheading:17908977-Drug Synergism,
pubmed-meshheading:17908977-Female,
pubmed-meshheading:17908977-Flavonoids,
pubmed-meshheading:17908977-Humans,
pubmed-meshheading:17908977-Male,
pubmed-meshheading:17908977-Middle Aged,
pubmed-meshheading:17908977-Neoplasms,
pubmed-meshheading:17908977-Piperidines,
pubmed-meshheading:17908977-Taxoids,
pubmed-meshheading:17908977-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors.
|
|
pubmed:affiliation |
Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
